5:29 PM
 | 
Dec 13, 2013
 |  BC Extra  |  Clinical News

Lesinurad meets in Phase III gout trial

AstraZeneca plc (LSE:AZN; NYSE:AZN) said once-daily lesinurad ( RDEA594) met the primary endpoint of a greater proportion of patients achieving serum uric acid (sUA) levels of less than 6 mg/dL at...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >